Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Helen Blair.

Newcastle AuthorsTitleYearFull text
Dr Ricky Tirtakusuma
Dr Paul Milne
Dr Helen Blair
Yuzhe Shi
Dr Simon Bomken
et al.
Fusion transcripts are present in early progenitor cells in KMT2A-rearranged B-ALL2024
Dr Sarah Fordham
Dr Wei-Yu Lin
Dr Helen Blair
Dr Claire Elstob
Dr Hayden Bell
et al.
Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia2023
Dr Paul Sinclair
Dr Ruth Cranston
Prahlad Raninga
Joanna Cheng
Rebecca Hanna
et al.
Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia2023
Dr Hayden Bell
Dr Helen Blair
Mankaran Singh
Professor Anthony Moorman
Professor Olaf Heidenreich
et al.
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia2023
Dr Helen Blair
Dr Katarzyna Szoltysek
Rachel Cameron
Professor Olaf Heidenreich
The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML2023
Aaron Wilson
Sean Hockney
Sharon Angel
Dr Helen Blair
Dr Deepali Pal
et al.
A human mesenchymal spheroid prototype to replace moderate severity animal procedures in leukaemia drug testing2022
Dr Jose Luis Marin-Rubio
Dr Maria Duenas Fadic
Dr Tiaan Heunis
Dr Abeer Dannoura
Dr Joe Inns
et al.
A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia2022
Dr Ricky Tirtakusuma
Dr Katarzyna Szoltysek
Professor Vasily Grinev
Dr Sirintra Nakjang
Dr Daniel Williamson
et al.
Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia2022
Dr Deepali Pal
Dr Helen Blair
Sean Hockney
Dr Melanie Beckett
Mankaran Singh
et al.
hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia2022
Toni Pringle
Dr Corey Chan
Dr Saimir Luli
Dr Helen Blair
Dr Kenneth Rankin
et al.
Synthesis and In Vivo Evaluation of a Site-specifically Labeled Radioimmunoconjugate for Dual-Modal (PET/NIRF) Imaging of MT1-MMP in Sarcomas2022
Dr Natalie Bell
Dr Helen Blair
Dr Simon Bomken
Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy2021
Yuzhe Shi
Melanie Beckett
Dr Helen Blair
Dr Ricky Tirtakusuma
Dr Sirintra Nakjang
et al.
Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia2021
Mankaran Singh
Dr Helen Blair
Philip Berry
Professor Olaf Heidenreich
Multi-drug chemotherapy dose optimisation in preclinical leukaemia models using HPLC-MS/MS2020
Liz Matheson
Huw Thomas
Marian Case
Dr Helen Blair
Rosanna Jackson
et al.
Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM2019
Dr Helen Blair
Professor Christine Harrison FRCPath FMedSci
Dr Lisa Russell
Single cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia2019
Dr Helen Blair
Professor Olaf Heidenreich
Subtype-specific regulatory network rewiring in acute myeloid leukemia2019
Dr Deepali Pal
Dr Helen Blair
Professor Olaf Heidenreich
Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia2019
Dr Paul Sinclair
Dr Helen Blair
Dr Sarra Ryan
Dr Lars Buechler
Joanna Cheng
et al.
Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 212018
Dr Sarah Fordham
Dr Helen Blair
Dr Claire Elstob
Professor Ruth Plummer
Dr Yvette Drew
et al.
Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase2018
Dr Lynsey McKenzie
Hasan Issa
Sandeep Potluri
Dr Helen Blair
Asmida Isa
et al.
The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation2018
Dr Alex Elder
Dr Simon Bomken
Dr Ian Wilson
Dr Helen Blair
Dr Simon Cockell
et al.
Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia2017
Dr Aiste McCormick
Gavin Cuthbert
Dr Rachel O'Donnell
Dr Brian Wilson
Huw Thomas
et al.
Functional characterisation of a novel ovarian cancer cell line, NUOC-12017
Dr Richard Noble
Dr Natalie Bell
Dr Helen Blair
Huw Thomas
Nicole Phillips
et al.
Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma2017
Dr Britta Vormoor
Yvonne Schlosser
Dr Helen Blair
Abhishek Sharma
Sarah Wilkinson
et al.
Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/22017
Dr Lynsey McKenzie
Dr Sirintra Nakjang
Dr Helen Blair
Professor Hermann Josef Vormoor
Professor Olaf Heidenreich
et al.
Identification of CCND2 As a RUNX1/ETO Target Required for Leukaemic Propagation2016
Dr Deepali Pal
Dr Helen Blair
Dr Alex Elder
Katie Dormon
Dr Kate Rennie
et al.
Long-term in vitro maintenance of clonal abundance and leukaemia-initiating potential in acute lymphoblastic leukaemia2016
Dr Alex Elder
Dr Klaus Rehe
Dr Simon Bomken
Dr Paul Sinclair
Katie Dormon
et al.
The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.2016
Dr Paul Sinclair
Joanna Cheng
Prahlad Raninga
Rebecca Hanna
Shaun Hollern
et al.
A Targeted Functional Clone Tracking Assay for the Identification of Tumour Suppressor Genes in BCP- ALL Implicates the Transcription Factors FOXO3 and PRDM12015
Katie Dormon
Elda Latif
Dr Matthew Bashton
Dr Deepali Pal
Dr Helen Blair
et al.
A Whole Genome In Vivo Crispr Screen in Primary ALL Predicts Leukaemic Relapse2015
Dr Alex Elder
Dr Helen Blair
Katie Dormon
Dr Simon Bomken
Dr Simon Cockell
et al.
High Abundance of Acute Lymphoblastic Leukaemia Founder Clones Does Not Translate to Functional Heterogeneity2015
Dr Britta Vormoor
Yvonne Schlosser
Dr Helen Blair
Sarah Wilkinson
Professor Herbie Newell
et al.
Inhibition of DNA-Repair Enzymes (DNA-Pk and Parp) to Sensitize Ewing Sarcoma to Chemo-And Radiotherapy2015
Dr Natalie Bell
Dr Helen Blair
Lisa Price
Dr Katrina Wood
Professor Hermann Josef Vormoor
et al.
Patient-derived xenograft and in vivo bioluminescent modelling of B-cell NHL2015
Dr Britta Vormoor
Henrike Knizia
Michael Batey
Dr Ian Wilson
Dr Petra Dildey
et al.
Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging2014
Dr Natalie Bell
Dr Helen Blair
Professor Hermann Josef Vormoor
Dr Christopher Bacon
Dr Vikki Rand
et al.
Development of in Vivo Models of Paediatric Burkitt Lymphoma Allowing Therapeutic Target Analysis and Drug Testing2014
Dr Alex Elder
Dr Simon Bomken
Dr Helen Blair
Professor Hermann Josef Vormoor
Professor Olaf Heidenreich
et al.
Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia2014
Dr Simon Bomken
Dr Helen Blair
Professor Hermann Josef Vormoor
Professor Olaf Heidenreich
Preclinical modelling of childhood acute lymphoblastic leukaemia2014
Professor Julie Irving
Elizabeth Matheson
Dr Helen Blair
Marian Case
Isabella Swidenbank
et al.
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition2014
Michael Batey
Dr Frida Ponthan
Dr Helen Blair
Professor Olaf Heidenreich
The development and evaluation of a series of novel in vivo imaging models of AML for the assessment of drug efficacy2014
Dr Mitsushiro Nakatomi
Dr Helen Blair
Katie MacArthur
Dr Victor Ruiz-Perez
Professor Judith Goodship
et al.
Evc regulates a symmetrical response to Shh signaling in molar development2013
Dr Simon Bomken
Dr Lars Buechler
Dr Klaus Rehe
Dr Frida Ponthan
Dr Alex Elder
et al.
Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression2013
Dr Helen Blair
Dr Stuart Tompson
Yu-Ning Liu
Dr Jennifer Campbell
Katie MacArthur
et al.
Evc2 is a positive modulator of Hedgehog signalling that interacts with Evc at the cilia membrane and is also found in the nucleus2011
Dr Simon Bomken
Dr Lars Buechler
Dr Klaus Rehe
Dr Frida Ponthan
Dr Helen Blair
et al.
Lentiviral Transduction of Patient Derived Leukaemic Blasts Allowing In Vivo Bioluminescent Monitoring in An NSG Model of Leukaemia Stem Cell Maintenance2011
Dr Helen Blair
Dr Stuart Tompson
Dr Jennifer Campbell
Professor Judith Goodship
Evc and Evc2 are interacting cilia transmembrane proteins that modulate Ihh signalling2009
Dr Victor Ruiz-Perez
Dr Helen Blair
Dr Colin Miles
Dr Heiko Peters
Professor Judith Goodship
et al.
Evc is a positive mediator of Ihh-regulated bone growth that localises at the base of chondrocyte cilia2007
Dr Stuart Tompson
Dr Victor Ruiz-Perez
Dr Helen Blair
Dr Michael Wright
Professor Judith Goodship
et al.
Sequencing EVC and EVC2 identifies mutations in two-thirds of Ellis-van Creveld syndrome patients2007
Dr Helen Blair
Dr Mark Buddles
Dr Ann Curtis
Professor Judith Goodship
Identification of a mutation in synapsin I, a synaptic vesicle protein, in a family with epilepsy2004
Professor Judith Goodship
Dr Helen Blair
Dr Mark Buddles
Dr Ann Curtis
Deficiency of synapsin I, a synaptic vesicle protein, causes epilepsy2003
Dr Victor Ruiz-Perez
Dr Stuart Tompson
Dr Helen Blair
Dr Michael Wright
Professor Judith Goodship
et al.
Mutations in two nonhomologous genes in a head-to-head configuration cause Ellis-van Creveld syndrome2003
Dr Helen Blair
Emeritus Professor Barry Hirst
Targeting polymerised liposome vaccine carriers to intestinal M cells2001
Dr Helen Blair
A phenotype map of the mouse X chromosome: Models for human X-linked disease2000
Dr Helen Blair
Positioning of five genes (CASK, ARX, SAT, IMAGE cDNAs 248928 and 253949 from the human X chromosome short arm with respect to evolutionary breakpoints on the mouse X chromosome2000